nodes	percent_of_prediction	percent_of_DWPC	metapath
Levonorgestrel—Ethinyl Estradiol—osteoporosis	0.23	1	CrCtD
Levonorgestrel—polycystic ovary syndrome—Ethinyl Estradiol—osteoporosis	0.186	1	CpDpCtD
Levonorgestrel—SHBG—osteoporosis	0.0673	0.415	CbGaD
Levonorgestrel—CYP19A1—osteoporosis	0.0494	0.305	CbGaD
Levonorgestrel—ESR1—osteoporosis	0.0455	0.28	CbGaD
Levonorgestrel—SHBG—Estropipate—osteoporosis	0.0285	0.162	CbGbCtD
Levonorgestrel—ESR1—Estropipate—osteoporosis	0.0206	0.117	CbGbCtD
Levonorgestrel—AR—Ergocalciferol—osteoporosis	0.0191	0.108	CbGbCtD
Levonorgestrel—SHBG—Ethinyl Estradiol—osteoporosis	0.0184	0.104	CbGbCtD
Levonorgestrel—Mestranol—Estropipate—osteoporosis	0.0142	0.0814	CrCrCtD
Levonorgestrel—Quinestrol—Estropipate—osteoporosis	0.0142	0.0814	CrCrCtD
Levonorgestrel—ESR1—Raloxifene—osteoporosis	0.0137	0.0779	CbGbCtD
Levonorgestrel—Ethinyl Estradiol—Estropipate—osteoporosis	0.0135	0.0775	CrCrCtD
Levonorgestrel—ESR1—Ethinyl Estradiol—osteoporosis	0.0133	0.0753	CbGbCtD
Levonorgestrel—Desogestrel—Ethinyl Estradiol—osteoporosis	0.0122	0.0699	CrCrCtD
Levonorgestrel—SHBG—Estradiol—osteoporosis	0.0118	0.0671	CbGbCtD
Levonorgestrel—CYP19A1—Raloxifene—osteoporosis	0.0111	0.0632	CbGbCtD
Levonorgestrel—Quinestrol—Conjugated Estrogens—osteoporosis	0.0108	0.0617	CrCrCtD
Levonorgestrel—Mestranol—Conjugated Estrogens—osteoporosis	0.0108	0.0617	CrCrCtD
Levonorgestrel—Ethinyl Estradiol—Conjugated Estrogens—osteoporosis	0.0103	0.0588	CrCrCtD
Levonorgestrel—Etonogestrel—Ethinyl Estradiol—osteoporosis	0.0101	0.0577	CrCrCtD
Levonorgestrel—AR—Estradiol—osteoporosis	0.0099	0.0561	CbGbCtD
Levonorgestrel—ESR1—Conjugated Estrogens—osteoporosis	0.00975	0.0552	CbGbCtD
Levonorgestrel—Norelgestromin—Ethinyl Estradiol—osteoporosis	0.00953	0.0546	CrCrCtD
Levonorgestrel—Mestranol—Estradiol—osteoporosis	0.00928	0.0531	CrCrCtD
Levonorgestrel—Quinestrol—Estradiol—osteoporosis	0.00928	0.0531	CrCrCtD
Levonorgestrel—Mestranol—Ethinyl Estradiol—osteoporosis	0.00905	0.0518	CrCrCtD
Levonorgestrel—Quinestrol—Ethinyl Estradiol—osteoporosis	0.00905	0.0518	CrCrCtD
Levonorgestrel—Ethinyl Estradiol—Estradiol—osteoporosis	0.00884	0.0506	CrCrCtD
Levonorgestrel—ESR1—Estradiol—osteoporosis	0.00856	0.0485	CbGbCtD
Levonorgestrel—Danazol—Ethinyl Estradiol—osteoporosis	0.00728	0.0417	CrCrCtD
Levonorgestrel—Norethindrone—Ethinyl Estradiol—osteoporosis	0.00634	0.0363	CrCrCtD
Levonorgestrel—Methyltestosterone—Ethinyl Estradiol—osteoporosis	0.0052	0.0298	CrCrCtD
Levonorgestrel—Testosterone—Estradiol—osteoporosis	0.00474	0.0272	CrCrCtD
Levonorgestrel—CYP3A4—Calcitriol—osteoporosis	0.00212	0.012	CbGbCtD
Levonorgestrel—CYP3A4—Estropipate—osteoporosis	0.00212	0.012	CbGbCtD
Levonorgestrel—CYP3A4—Ergocalciferol—osteoporosis	0.00169	0.00959	CbGbCtD
Levonorgestrel—CYP3A4—Raloxifene—osteoporosis	0.00141	0.008	CbGbCtD
Levonorgestrel—CYP3A4—Ethinyl Estradiol—osteoporosis	0.00136	0.00773	CbGbCtD
Levonorgestrel—CYP3A4—Cholecalciferol—osteoporosis	0.00109	0.00618	CbGbCtD
Levonorgestrel—CYP3A4—Conjugated Estrogens—osteoporosis	0.001	0.00567	CbGbCtD
Levonorgestrel—CYP3A4—Estradiol—osteoporosis	0.000879	0.00498	CbGbCtD
Levonorgestrel—Desogestrel—SHBG—osteoporosis	0.00011	0.0757	CrCbGaD
Levonorgestrel—Quinestrol—ESR1—osteoporosis	9.9e-05	0.0683	CrCbGaD
Levonorgestrel—Nandrolone phenpropionate—CYP19A1—osteoporosis	9.15e-05	0.0631	CrCbGaD
Levonorgestrel—Etonogestrel—SHBG—osteoporosis	8.88e-05	0.0613	CrCbGaD
Levonorgestrel—Ethynodiol—ESR1—osteoporosis	8.15e-05	0.0562	CrCbGaD
Levonorgestrel—Allylestrenol—ESR1—osteoporosis	7.7e-05	0.0531	CrCbGaD
Levonorgestrel—Mestranol—ESR1—osteoporosis	7.5e-05	0.0518	CrCbGaD
Levonorgestrel—Desogestrel—ESR1—osteoporosis	7.41e-05	0.0511	CrCbGaD
Levonorgestrel—Nandrolone decanoate—CYP19A1—osteoporosis	6.93e-05	0.0478	CrCbGaD
Levonorgestrel—Norgestimate—ESR1—osteoporosis	6.93e-05	0.0478	CrCbGaD
Levonorgestrel—Etonogestrel—ESR1—osteoporosis	6e-05	0.0414	CrCbGaD
Levonorgestrel—Ethinyl Estradiol—ESR2—osteoporosis	5.81e-05	0.0401	CrCbGaD
Levonorgestrel—Danazol—SHBG—osteoporosis	5.72e-05	0.0395	CrCbGaD
Levonorgestrel—Ethinyl Estradiol—SHBG—osteoporosis	5.3e-05	0.0365	CrCbGaD
Levonorgestrel—Norethindrone—SHBG—osteoporosis	5.09e-05	0.0351	CrCbGaD
Levonorgestrel—Methyltestosterone—SHBG—osteoporosis	4.84e-05	0.0334	CrCbGaD
Levonorgestrel—Danazol—CYP19A1—osteoporosis	4.2e-05	0.029	CrCbGaD
Levonorgestrel—SRD5A1—Metabolism—IDH2—osteoporosis	4.13e-05	0.00349	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Breast Cancer Pathway—RAP1A—osteoporosis	3.98e-05	0.00336	CbGpPWpGaD
Levonorgestrel—SRD5A1—Metabolism—CYP27A1—osteoporosis	3.88e-05	0.00328	CbGpPWpGaD
Levonorgestrel—Danazol—ESR1—osteoporosis	3.87e-05	0.0267	CrCbGaD
Levonorgestrel—SRD5A1—Metabolism—ACP5—osteoporosis	3.78e-05	0.00319	CbGpPWpGaD
Levonorgestrel—SRD5A1—Metabolism of lipids and lipoproteins—GPX1—osteoporosis	3.73e-05	0.00315	CbGpPWpGaD
Levonorgestrel—ESR1—Regulation of nuclear SMAD2/3 signaling—VDR—osteoporosis	3.7e-05	0.00313	CbGpPWpGaD
Levonorgestrel—AR—Regulation of nuclear SMAD2/3 signaling—ESR1—osteoporosis	3.67e-05	0.0031	CbGpPWpGaD
Levonorgestrel—Hydrocortisone—SHBG—osteoporosis	3.64e-05	0.0251	CrCbGaD
Levonorgestrel—CYP19A1—Cytochrome P450 - arranged by substrate type—POMC—osteoporosis	3.61e-05	0.00305	CbGpPWpGaD
Levonorgestrel—AR—SIDS Susceptibility Pathways—ESR2—osteoporosis	3.58e-05	0.00303	CbGpPWpGaD
Levonorgestrel—Ethinyl Estradiol—ESR1—osteoporosis	3.58e-05	0.0247	CrCbGaD
Levonorgestrel—Methyltestosterone—CYP19A1—osteoporosis	3.55e-05	0.0245	CrCbGaD
Levonorgestrel—SRD5A1—Metabolism—TPI1—osteoporosis	3.51e-05	0.00297	CbGpPWpGaD
Levonorgestrel—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP27A1—osteoporosis	3.34e-05	0.00282	CbGpPWpGaD
Levonorgestrel—AR—Integrated Breast Cancer Pathway—CYP19A1—osteoporosis	3.34e-05	0.00282	CbGpPWpGaD
Levonorgestrel—SRD5A1—Metabolism—P4HB—osteoporosis	3.3e-05	0.00279	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Pancreatic Cancer Pathway—RAP1A—osteoporosis	3.3e-05	0.00279	CbGpPWpGaD
Levonorgestrel—CYP3A4—Oxidation by Cytochrome P450—CYP27A1—osteoporosis	3.3e-05	0.00279	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism of lipids and lipoproteins—FDPS—osteoporosis	3.3e-05	0.00278	CbGpPWpGaD
Levonorgestrel—SRD5A1—Metabolism—GAPDH—osteoporosis	3.24e-05	0.00274	CbGpPWpGaD
Levonorgestrel—SRD5A1—Metabolism—RAP1A—osteoporosis	3.16e-05	0.00267	CbGpPWpGaD
Levonorgestrel—ESR1—Leptin signaling pathway—LEP—osteoporosis	3.15e-05	0.00266	CbGpPWpGaD
Levonorgestrel—CYP3A4—Farnesoid X Receptor  Pathway—IRS2—osteoporosis	3.15e-05	0.00266	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism of lipids and lipoproteins—GPD2—osteoporosis	3.12e-05	0.00264	CbGpPWpGaD
Levonorgestrel—PGR—Signaling by ERBB4—IRS2—osteoporosis	3.12e-05	0.00263	CbGpPWpGaD
Levonorgestrel—AR—Integrated Pancreatic Cancer Pathway—ESR2—osteoporosis	3.05e-05	0.00257	CbGpPWpGaD
Levonorgestrel—PGR—Validated nuclear estrogen receptor alpha network—MYC—osteoporosis	3.03e-05	0.00256	CbGpPWpGaD
Levonorgestrel—Progesterone—SHBG—osteoporosis	2.97e-05	0.0205	CrCbGaD
Levonorgestrel—CYP19A1—Phase 1 - Functionalization of compounds—POMC—osteoporosis	2.93e-05	0.00247	CbGpPWpGaD
Levonorgestrel—PGR—Signaling by ERBB4—ESR1—osteoporosis	2.91e-05	0.00246	CbGpPWpGaD
Levonorgestrel—ESR1—Leptin signaling pathway—IRS1—osteoporosis	2.81e-05	0.00237	CbGpPWpGaD
Levonorgestrel—Testosterone—SHBG—osteoporosis	2.81e-05	0.0193	CrCbGaD
Levonorgestrel—SRD5A1—Metabolism of lipids and lipoproteins—POMC—osteoporosis	2.75e-05	0.00232	CbGpPWpGaD
Levonorgestrel—PGR—Signaling by ERBB4—IRS1—osteoporosis	2.72e-05	0.0023	CbGpPWpGaD
Levonorgestrel—CYP3A4—Phase 1 - Functionalization of compounds—CYP27A1—osteoporosis	2.71e-05	0.00229	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling by ERBB4—KL—osteoporosis	2.67e-05	0.00226	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Breast Cancer Pathway—CYP19A1—osteoporosis	2.57e-05	0.00217	CbGpPWpGaD
Levonorgestrel—PGR—Signaling by ERBB4—IL6R—osteoporosis	2.56e-05	0.00216	CbGpPWpGaD
Levonorgestrel—SRD5A1—Metabolism—ENO1—osteoporosis	2.55e-05	0.00215	CbGpPWpGaD
Levonorgestrel—SRD5A1—Metabolism—PSMA5—osteoporosis	2.51e-05	0.00212	CbGpPWpGaD
Levonorgestrel—SRD5A1—Metabolism—PSMA2—osteoporosis	2.51e-05	0.00212	CbGpPWpGaD
Levonorgestrel—PGR—Gene Expression—U2AF1—osteoporosis	2.5e-05	0.00211	CbGpPWpGaD
Levonorgestrel—ESR1—FOXM1 transcription factor network—MYC—osteoporosis	2.49e-05	0.0021	CbGpPWpGaD
Levonorgestrel—ESR1—LKB1 signaling events—MYC—osteoporosis	2.44e-05	0.00206	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism of lipids and lipoproteins—OXCT1—osteoporosis	2.43e-05	0.00205	CbGpPWpGaD
Levonorgestrel—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—osteoporosis	2.42e-05	0.00204	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism of lipids and lipoproteins—MGLL—osteoporosis	2.37e-05	0.002	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Pancreatic Cancer Pathway—ESR2—osteoporosis	2.35e-05	0.00198	CbGpPWpGaD
Levonorgestrel—ESR1—Aryl Hydrocarbon Receptor—MYC—osteoporosis	2.31e-05	0.00195	CbGpPWpGaD
Levonorgestrel—AR—Integrated Breast Cancer Pathway—ESR1—osteoporosis	2.23e-05	0.00188	CbGpPWpGaD
Levonorgestrel—CYP3A4—Tryptophan metabolism—CYP19A1—osteoporosis	2.17e-05	0.00183	CbGpPWpGaD
Levonorgestrel—ESR1—Aryl Hydrocarbon Receptor—TNF—osteoporosis	2.15e-05	0.00182	CbGpPWpGaD
Levonorgestrel—AR—Integrated Breast Cancer Pathway—IRS1—osteoporosis	2.08e-05	0.00176	CbGpPWpGaD
Levonorgestrel—Testosterone—CYP19A1—osteoporosis	2.06e-05	0.0142	CrCbGaD
Levonorgestrel—SRD5A1—Metabolism—CYP19A1—osteoporosis	2.04e-05	0.00172	CbGpPWpGaD
Levonorgestrel—Cough—Zoledronate—osteoporosis	2.02e-05	0.000354	CcSEcCtD
Levonorgestrel—Connective tissue disorder—Estradiol—osteoporosis	2.02e-05	0.000353	CcSEcCtD
Levonorgestrel—Urethral disorder—Estradiol—osteoporosis	2.01e-05	0.000352	CcSEcCtD
Levonorgestrel—Rash—Etidronic acid—osteoporosis	2.01e-05	0.000352	CcSEcCtD
Levonorgestrel—ESR1—Leptin signaling pathway—IL1B—osteoporosis	2.01e-05	0.0017	CbGpPWpGaD
Levonorgestrel—Dermatitis—Etidronic acid—osteoporosis	2.01e-05	0.000351	CcSEcCtD
Levonorgestrel—Vertigo—Conjugated Estrogens—osteoporosis	2.01e-05	0.000351	CcSEcCtD
Levonorgestrel—Progesterone—ESR1—osteoporosis	2e-05	0.0138	CrCbGaD
Levonorgestrel—Hyperhidrosis—Pamidronate—osteoporosis	2e-05	0.00035	CcSEcCtD
Levonorgestrel—Syncope—Conjugated Estrogens—osteoporosis	2e-05	0.00035	CcSEcCtD
Levonorgestrel—Hypertension—Zoledronate—osteoporosis	2e-05	0.00035	CcSEcCtD
Levonorgestrel—Hypersensitivity—Alendronate—osteoporosis	2e-05	0.00035	CcSEcCtD
Levonorgestrel—Headache—Etidronic acid—osteoporosis	2e-05	0.000349	CcSEcCtD
Levonorgestrel—PGR—Generic Transcription Pathway—ESR2—osteoporosis	1.99e-05	0.00168	CbGpPWpGaD
Levonorgestrel—Musculoskeletal discomfort—Risedronate—osteoporosis	1.99e-05	0.000347	CcSEcCtD
Levonorgestrel—Asthenia—Estropipate—osteoporosis	1.98e-05	0.000346	CcSEcCtD
Levonorgestrel—Visual impairment—Estradiol—osteoporosis	1.98e-05	0.000346	CcSEcCtD
Levonorgestrel—Anorexia—Pamidronate—osteoporosis	1.97e-05	0.000345	CcSEcCtD
Levonorgestrel—Myalgia—Zoledronate—osteoporosis	1.97e-05	0.000345	CcSEcCtD
Levonorgestrel—Chest pain—Zoledronate—osteoporosis	1.97e-05	0.000345	CcSEcCtD
Levonorgestrel—Palpitations—Conjugated Estrogens—osteoporosis	1.97e-05	0.000345	CcSEcCtD
Levonorgestrel—Insomnia—Risedronate—osteoporosis	1.97e-05	0.000345	CcSEcCtD
Levonorgestrel—Anxiety—Zoledronate—osteoporosis	1.97e-05	0.000344	CcSEcCtD
Levonorgestrel—Loss of consciousness—Conjugated Estrogens—osteoporosis	1.96e-05	0.000343	CcSEcCtD
Levonorgestrel—Unspecified disorder of skin and subcutaneous tissue—Zoledronate—osteoporosis	1.96e-05	0.000343	CcSEcCtD
Levonorgestrel—Pruritus—Estropipate—osteoporosis	1.95e-05	0.000341	CcSEcCtD
Levonorgestrel—Discomfort—Zoledronate—osteoporosis	1.95e-05	0.000341	CcSEcCtD
Levonorgestrel—Asthenia—Alendronate—osteoporosis	1.95e-05	0.000341	CcSEcCtD
Levonorgestrel—Hypersensitivity—Ibandronate—osteoporosis	1.95e-05	0.000341	CcSEcCtD
Levonorgestrel—Cough—Conjugated Estrogens—osteoporosis	1.95e-05	0.000341	CcSEcCtD
Levonorgestrel—Dyspnoea—Risedronate—osteoporosis	1.94e-05	0.00034	CcSEcCtD
Levonorgestrel—Erythema multiforme—Estradiol—osteoporosis	1.94e-05	0.000339	CcSEcCtD
Levonorgestrel—Gastrointestinal disorder—Ethinyl Estradiol—osteoporosis	1.93e-05	0.000338	CcSEcCtD
Levonorgestrel—AR—Regulation of nuclear beta catenin signaling and target gene transcription—MYC—osteoporosis	1.93e-05	0.00163	CbGpPWpGaD
Levonorgestrel—Fatigue—Ethinyl Estradiol—osteoporosis	1.93e-05	0.000337	CcSEcCtD
Levonorgestrel—Pruritus—Alendronate—osteoporosis	1.92e-05	0.000336	CcSEcCtD
Levonorgestrel—CYP19A1—Integrated Breast Cancer Pathway—ESR1—osteoporosis	1.92e-05	0.00162	CbGpPWpGaD
Levonorgestrel—Dyspepsia—Risedronate—osteoporosis	1.92e-05	0.000336	CcSEcCtD
Levonorgestrel—Eye disorder—Estradiol—osteoporosis	1.92e-05	0.000336	CcSEcCtD
Levonorgestrel—Constipation—Ethinyl Estradiol—osteoporosis	1.91e-05	0.000334	CcSEcCtD
Levonorgestrel—AR—Regulation of nuclear SMAD2/3 signaling—MYC—osteoporosis	1.91e-05	0.00161	CbGpPWpGaD
Levonorgestrel—AR—SIDS Susceptibility Pathways—IL6R—osteoporosis	1.91e-05	0.00161	CbGpPWpGaD
Levonorgestrel—Hypersensitivity—Calcitriol—osteoporosis	1.91e-05	0.000334	CcSEcCtD
Levonorgestrel—Cardiac disorder—Estradiol—osteoporosis	1.91e-05	0.000333	CcSEcCtD
Levonorgestrel—AR—Gene Expression—U2AF1—osteoporosis	1.9e-05	0.00161	CbGpPWpGaD
Levonorgestrel—Chest pain—Conjugated Estrogens—osteoporosis	1.9e-05	0.000332	CcSEcCtD
Levonorgestrel—Myalgia—Conjugated Estrogens—osteoporosis	1.9e-05	0.000332	CcSEcCtD
Levonorgestrel—Asthenia—Ibandronate—osteoporosis	1.9e-05	0.000332	CcSEcCtD
Levonorgestrel—Anxiety—Conjugated Estrogens—osteoporosis	1.89e-05	0.000331	CcSEcCtD
Levonorgestrel—Nausea—Etidronic acid—osteoporosis	1.89e-05	0.000331	CcSEcCtD
Levonorgestrel—CYP19A1—Metabolism of lipids and lipoproteins—CYP27A1—osteoporosis	1.89e-05	0.0016	CbGpPWpGaD
Levonorgestrel—Oedema—Zoledronate—osteoporosis	1.89e-05	0.000331	CcSEcCtD
Levonorgestrel—Unspecified disorder of skin and subcutaneous tissue—Conjugated Estrogens—osteoporosis	1.89e-05	0.00033	CcSEcCtD
Levonorgestrel—Musculoskeletal discomfort—Pamidronate—osteoporosis	1.89e-05	0.00033	CcSEcCtD
Levonorgestrel—Diarrhoea—Estropipate—osteoporosis	1.89e-05	0.00033	CcSEcCtD
Levonorgestrel—Gastrointestinal disorder—Risedronate—osteoporosis	1.88e-05	0.000329	CcSEcCtD
Levonorgestrel—Infection—Zoledronate—osteoporosis	1.88e-05	0.000329	CcSEcCtD
Levonorgestrel—Fatigue—Risedronate—osteoporosis	1.88e-05	0.000329	CcSEcCtD
Levonorgestrel—Insomnia—Pamidronate—osteoporosis	1.87e-05	0.000328	CcSEcCtD
Levonorgestrel—PGR—Signaling Pathways—SOST—osteoporosis	1.87e-05	0.00158	CbGpPWpGaD
Levonorgestrel—Pruritus—Ibandronate—osteoporosis	1.87e-05	0.000327	CcSEcCtD
Levonorgestrel—Pain—Risedronate—osteoporosis	1.86e-05	0.000326	CcSEcCtD
Levonorgestrel—Constipation—Risedronate—osteoporosis	1.86e-05	0.000326	CcSEcCtD
Levonorgestrel—Shock—Zoledronate—osteoporosis	1.86e-05	0.000326	CcSEcCtD
Levonorgestrel—Diarrhoea—Alendronate—osteoporosis	1.86e-05	0.000325	CcSEcCtD
Levonorgestrel—Asthenia—Calcitriol—osteoporosis	1.86e-05	0.000325	CcSEcCtD
Levonorgestrel—Nervous system disorder—Zoledronate—osteoporosis	1.86e-05	0.000325	CcSEcCtD
Levonorgestrel—PGR—Gene Expression—RPL24—osteoporosis	1.86e-05	0.00157	CbGpPWpGaD
Levonorgestrel—Immune system disorder—Estradiol—osteoporosis	1.85e-05	0.000324	CcSEcCtD
Levonorgestrel—Mediastinal disorder—Estradiol—osteoporosis	1.85e-05	0.000324	CcSEcCtD
Levonorgestrel—AR—Integrated Pancreatic Cancer Pathway—ESR1—osteoporosis	1.85e-05	0.00156	CbGpPWpGaD
Levonorgestrel—Dyspnoea—Pamidronate—osteoporosis	1.85e-05	0.000323	CcSEcCtD
Levonorgestrel—Somnolence—Pamidronate—osteoporosis	1.84e-05	0.000322	CcSEcCtD
Levonorgestrel—Skin disorder—Zoledronate—osteoporosis	1.84e-05	0.000321	CcSEcCtD
Levonorgestrel—Pruritus—Calcitriol—osteoporosis	1.83e-05	0.00032	CcSEcCtD
Levonorgestrel—ESR1—Signaling by ERBB4—IRS2—osteoporosis	1.83e-05	0.00155	CbGpPWpGaD
Levonorgestrel—Hyperhidrosis—Zoledronate—osteoporosis	1.83e-05	0.00032	CcSEcCtD
Levonorgestrel—Gastrointestinal pain—Ethinyl Estradiol—osteoporosis	1.83e-05	0.00032	CcSEcCtD
Levonorgestrel—Diarrhoea—Raloxifene—osteoporosis	1.83e-05	0.00032	CcSEcCtD
Levonorgestrel—Dyspepsia—Pamidronate—osteoporosis	1.82e-05	0.000319	CcSEcCtD
Levonorgestrel—Dizziness—Estropipate—osteoporosis	1.82e-05	0.000319	CcSEcCtD
Levonorgestrel—Oedema—Conjugated Estrogens—osteoporosis	1.82e-05	0.000319	CcSEcCtD
Levonorgestrel—Alopecia—Estradiol—osteoporosis	1.81e-05	0.000317	CcSEcCtD
Levonorgestrel—Infection—Conjugated Estrogens—osteoporosis	1.81e-05	0.000317	CcSEcCtD
Levonorgestrel—Diarrhoea—Ibandronate—osteoporosis	1.81e-05	0.000316	CcSEcCtD
Levonorgestrel—Anorexia—Zoledronate—osteoporosis	1.8e-05	0.000315	CcSEcCtD
Levonorgestrel—Decreased appetite—Pamidronate—osteoporosis	1.8e-05	0.000315	CcSEcCtD
Levonorgestrel—Mental disorder—Estradiol—osteoporosis	1.8e-05	0.000315	CcSEcCtD
Levonorgestrel—Dizziness—Alendronate—osteoporosis	1.8e-05	0.000314	CcSEcCtD
Levonorgestrel—CYP19A1—Integrated Breast Cancer Pathway—IRS1—osteoporosis	1.79e-05	0.00152	CbGpPWpGaD
Levonorgestrel—Shock—Conjugated Estrogens—osteoporosis	1.79e-05	0.000314	CcSEcCtD
Levonorgestrel—Gastrointestinal disorder—Pamidronate—osteoporosis	1.79e-05	0.000313	CcSEcCtD
Levonorgestrel—Nervous system disorder—Conjugated Estrogens—osteoporosis	1.79e-05	0.000313	CcSEcCtD
Levonorgestrel—Erythema—Estradiol—osteoporosis	1.79e-05	0.000313	CcSEcCtD
Levonorgestrel—Malnutrition—Estradiol—osteoporosis	1.79e-05	0.000313	CcSEcCtD
Levonorgestrel—Fatigue—Pamidronate—osteoporosis	1.79e-05	0.000312	CcSEcCtD
Levonorgestrel—Gastrointestinal pain—Risedronate—osteoporosis	1.78e-05	0.000312	CcSEcCtD
Levonorgestrel—ESR1—Validated nuclear estrogen receptor alpha network—MYC—osteoporosis	1.78e-05	0.0015	CbGpPWpGaD
Levonorgestrel—Urticaria—Ethinyl Estradiol—osteoporosis	1.78e-05	0.000311	CcSEcCtD
Levonorgestrel—Constipation—Pamidronate—osteoporosis	1.77e-05	0.00031	CcSEcCtD
Levonorgestrel—Pain—Pamidronate—osteoporosis	1.77e-05	0.00031	CcSEcCtD
Levonorgestrel—Diarrhoea—Calcitriol—osteoporosis	1.77e-05	0.00031	CcSEcCtD
Levonorgestrel—Skin disorder—Conjugated Estrogens—osteoporosis	1.77e-05	0.00031	CcSEcCtD
Levonorgestrel—Abdominal pain—Ethinyl Estradiol—osteoporosis	1.77e-05	0.000309	CcSEcCtD
Levonorgestrel—Body temperature increased—Ethinyl Estradiol—osteoporosis	1.77e-05	0.000309	CcSEcCtD
Levonorgestrel—Dizziness—Raloxifene—osteoporosis	1.77e-05	0.000309	CcSEcCtD
Levonorgestrel—Hyperhidrosis—Conjugated Estrogens—osteoporosis	1.76e-05	0.000308	CcSEcCtD
Levonorgestrel—Flatulence—Estradiol—osteoporosis	1.76e-05	0.000308	CcSEcCtD
Levonorgestrel—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP19A1—osteoporosis	1.76e-05	0.00148	CbGpPWpGaD
Levonorgestrel—Tension—Estradiol—osteoporosis	1.75e-05	0.000307	CcSEcCtD
Levonorgestrel—Vomiting—Estropipate—osteoporosis	1.75e-05	0.000307	CcSEcCtD
Levonorgestrel—Dizziness—Ibandronate—osteoporosis	1.75e-05	0.000306	CcSEcCtD
Levonorgestrel—Rash—Estropipate—osteoporosis	1.74e-05	0.000304	CcSEcCtD
Levonorgestrel—Dermatitis—Estropipate—osteoporosis	1.74e-05	0.000304	CcSEcCtD
Levonorgestrel—Anorexia—Conjugated Estrogens—osteoporosis	1.74e-05	0.000304	CcSEcCtD
Levonorgestrel—Nervousness—Estradiol—osteoporosis	1.74e-05	0.000304	CcSEcCtD
Levonorgestrel—CYP3A4—Oxidation by Cytochrome P450—CYP19A1—osteoporosis	1.73e-05	0.00146	CbGpPWpGaD
Levonorgestrel—Urticaria—Risedronate—osteoporosis	1.73e-05	0.000303	CcSEcCtD
Levonorgestrel—Back pain—Estradiol—osteoporosis	1.73e-05	0.000302	CcSEcCtD
Levonorgestrel—Headache—Estropipate—osteoporosis	1.73e-05	0.000302	CcSEcCtD
Levonorgestrel—Vomiting—Alendronate—osteoporosis	1.73e-05	0.000302	CcSEcCtD
Levonorgestrel—Musculoskeletal discomfort—Zoledronate—osteoporosis	1.72e-05	0.000302	CcSEcCtD
Levonorgestrel—Abdominal pain—Risedronate—osteoporosis	1.72e-05	0.000301	CcSEcCtD
Levonorgestrel—Body temperature increased—Risedronate—osteoporosis	1.72e-05	0.000301	CcSEcCtD
Levonorgestrel—Muscle spasms—Estradiol—osteoporosis	1.72e-05	0.0003	CcSEcCtD
Levonorgestrel—Rash—Alendronate—osteoporosis	1.71e-05	0.0003	CcSEcCtD
Levonorgestrel—Insomnia—Zoledronate—osteoporosis	1.71e-05	0.000299	CcSEcCtD
Levonorgestrel—Dermatitis—Alendronate—osteoporosis	1.71e-05	0.000299	CcSEcCtD
Levonorgestrel—Headache—Alendronate—osteoporosis	1.7e-05	0.000298	CcSEcCtD
Levonorgestrel—Vomiting—Raloxifene—osteoporosis	1.7e-05	0.000297	CcSEcCtD
Levonorgestrel—Gastrointestinal pain—Pamidronate—osteoporosis	1.69e-05	0.000296	CcSEcCtD
Levonorgestrel—PGR—Signaling Pathways—PTH1R—osteoporosis	1.69e-05	0.00143	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—CALCR—osteoporosis	1.69e-05	0.00143	CbGpPWpGaD
Levonorgestrel—ESR1—Regulation of Telomerase—MYC—osteoporosis	1.69e-05	0.00143	CbGpPWpGaD
Levonorgestrel—ESR1—Regulation of Telomerase—TGFB1—osteoporosis	1.69e-05	0.00143	CbGpPWpGaD
Levonorgestrel—Dyspnoea—Zoledronate—osteoporosis	1.69e-05	0.000295	CcSEcCtD
Levonorgestrel—Rash—Raloxifene—osteoporosis	1.68e-05	0.000295	CcSEcCtD
Levonorgestrel—Dermatitis—Raloxifene—osteoporosis	1.68e-05	0.000294	CcSEcCtD
Levonorgestrel—Somnolence—Zoledronate—osteoporosis	1.68e-05	0.000294	CcSEcCtD
Levonorgestrel—Vomiting—Ibandronate—osteoporosis	1.68e-05	0.000294	CcSEcCtD
Levonorgestrel—Headache—Raloxifene—osteoporosis	1.67e-05	0.000293	CcSEcCtD
Levonorgestrel—Rash—Ibandronate—osteoporosis	1.67e-05	0.000292	CcSEcCtD
Levonorgestrel—SRD5A1—Metabolism—ADCY5—osteoporosis	1.67e-05	0.00141	CbGpPWpGaD
Levonorgestrel—Dermatitis—Ibandronate—osteoporosis	1.67e-05	0.000291	CcSEcCtD
Levonorgestrel—Dyspepsia—Zoledronate—osteoporosis	1.67e-05	0.000291	CcSEcCtD
Levonorgestrel—SRD5A1—Metabolism—GPX1—osteoporosis	1.66e-05	0.0014	CbGpPWpGaD
Levonorgestrel—Musculoskeletal discomfort—Conjugated Estrogens—osteoporosis	1.66e-05	0.00029	CcSEcCtD
Levonorgestrel—Headache—Ibandronate—osteoporosis	1.66e-05	0.00029	CcSEcCtD
Levonorgestrel—ESR1—AP-1 transcription factor network—MYC—osteoporosis	1.65e-05	0.0014	CbGpPWpGaD
Levonorgestrel—ESR1—AP-1 transcription factor network—TGFB1—osteoporosis	1.65e-05	0.00139	CbGpPWpGaD
Levonorgestrel—Insomnia—Conjugated Estrogens—osteoporosis	1.65e-05	0.000288	CcSEcCtD
Levonorgestrel—Hypersensitivity—Ethinyl Estradiol—osteoporosis	1.65e-05	0.000288	CcSEcCtD
Levonorgestrel—Vomiting—Calcitriol—osteoporosis	1.65e-05	0.000288	CcSEcCtD
Levonorgestrel—Decreased appetite—Zoledronate—osteoporosis	1.65e-05	0.000288	CcSEcCtD
Levonorgestrel—Nausea—Estropipate—osteoporosis	1.64e-05	0.000286	CcSEcCtD
Levonorgestrel—Body temperature increased—Pamidronate—osteoporosis	1.64e-05	0.000286	CcSEcCtD
Levonorgestrel—Abdominal pain—Pamidronate—osteoporosis	1.64e-05	0.000286	CcSEcCtD
Levonorgestrel—Gastrointestinal disorder—Zoledronate—osteoporosis	1.63e-05	0.000286	CcSEcCtD
Levonorgestrel—Angioedema—Estradiol—osteoporosis	1.63e-05	0.000286	CcSEcCtD
Levonorgestrel—Rash—Calcitriol—osteoporosis	1.63e-05	0.000285	CcSEcCtD
Levonorgestrel—Fatigue—Zoledronate—osteoporosis	1.63e-05	0.000285	CcSEcCtD
Levonorgestrel—Dermatitis—Calcitriol—osteoporosis	1.63e-05	0.000285	CcSEcCtD
Levonorgestrel—Dyspnoea—Conjugated Estrogens—osteoporosis	1.62e-05	0.000284	CcSEcCtD
Levonorgestrel—Headache—Calcitriol—osteoporosis	1.62e-05	0.000284	CcSEcCtD
Levonorgestrel—Somnolence—Conjugated Estrogens—osteoporosis	1.62e-05	0.000283	CcSEcCtD
Levonorgestrel—Pain—Zoledronate—osteoporosis	1.62e-05	0.000283	CcSEcCtD
Levonorgestrel—Constipation—Zoledronate—osteoporosis	1.62e-05	0.000283	CcSEcCtD
Levonorgestrel—Nausea—Alendronate—osteoporosis	1.61e-05	0.000282	CcSEcCtD
Levonorgestrel—CYP19A1—Metabolism of lipids and lipoproteins—P4HB—osteoporosis	1.61e-05	0.00136	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Breast Cancer Pathway—IRS1—osteoporosis	1.61e-05	0.00136	CbGpPWpGaD
Levonorgestrel—Hypersensitivity—Risedronate—osteoporosis	1.61e-05	0.000281	CcSEcCtD
Levonorgestrel—Vertigo—Estradiol—osteoporosis	1.61e-05	0.000281	CcSEcCtD
Levonorgestrel—Dyspepsia—Conjugated Estrogens—osteoporosis	1.6e-05	0.000281	CcSEcCtD
Levonorgestrel—Asthenia—Ethinyl Estradiol—osteoporosis	1.6e-05	0.00028	CcSEcCtD
Levonorgestrel—Syncope—Estradiol—osteoporosis	1.6e-05	0.00028	CcSEcCtD
Levonorgestrel—AR—Integrated Pancreatic Cancer Pathway—IGF1—osteoporosis	1.6e-05	0.00135	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling by ERBB4—IRS1—osteoporosis	1.6e-05	0.00135	CbGpPWpGaD
Levonorgestrel—Nausea—Raloxifene—osteoporosis	1.59e-05	0.000278	CcSEcCtD
Levonorgestrel—Decreased appetite—Conjugated Estrogens—osteoporosis	1.58e-05	0.000277	CcSEcCtD
Levonorgestrel—Pruritus—Ethinyl Estradiol—osteoporosis	1.58e-05	0.000277	CcSEcCtD
Levonorgestrel—Palpitations—Estradiol—osteoporosis	1.58e-05	0.000276	CcSEcCtD
Levonorgestrel—PGR—Generic Transcription Pathway—VDR—osteoporosis	1.58e-05	0.00133	CbGpPWpGaD
Levonorgestrel—Gastrointestinal disorder—Conjugated Estrogens—osteoporosis	1.57e-05	0.000275	CcSEcCtD
Levonorgestrel—Fatigue—Conjugated Estrogens—osteoporosis	1.57e-05	0.000275	CcSEcCtD
Levonorgestrel—Nausea—Ibandronate—osteoporosis	1.57e-05	0.000275	CcSEcCtD
Levonorgestrel—Loss of consciousness—Estradiol—osteoporosis	1.57e-05	0.000275	CcSEcCtD
Levonorgestrel—Asthenia—Risedronate—osteoporosis	1.56e-05	0.000273	CcSEcCtD
Levonorgestrel—Cough—Estradiol—osteoporosis	1.56e-05	0.000273	CcSEcCtD
Levonorgestrel—Pain—Conjugated Estrogens—osteoporosis	1.56e-05	0.000273	CcSEcCtD
Levonorgestrel—Constipation—Conjugated Estrogens—osteoporosis	1.56e-05	0.000273	CcSEcCtD
Levonorgestrel—CYP19A1—Biological oxidations—POMC—osteoporosis	1.56e-05	0.00131	CbGpPWpGaD
Levonorgestrel—Gastrointestinal pain—Zoledronate—osteoporosis	1.55e-05	0.000271	CcSEcCtD
Levonorgestrel—Hypertension—Estradiol—osteoporosis	1.54e-05	0.00027	CcSEcCtD
Levonorgestrel—Pruritus—Risedronate—osteoporosis	1.54e-05	0.00027	CcSEcCtD
Levonorgestrel—Nausea—Calcitriol—osteoporosis	1.54e-05	0.000269	CcSEcCtD
Levonorgestrel—SRD5A1—Metabolism—MTHFR—osteoporosis	1.53e-05	0.00129	CbGpPWpGaD
Levonorgestrel—Diarrhoea—Ethinyl Estradiol—osteoporosis	1.53e-05	0.000267	CcSEcCtD
Levonorgestrel—Hypersensitivity—Pamidronate—osteoporosis	1.53e-05	0.000267	CcSEcCtD
Levonorgestrel—Chest pain—Estradiol—osteoporosis	1.52e-05	0.000266	CcSEcCtD
Levonorgestrel—Myalgia—Estradiol—osteoporosis	1.52e-05	0.000266	CcSEcCtD
Levonorgestrel—Anxiety—Estradiol—osteoporosis	1.52e-05	0.000265	CcSEcCtD
Levonorgestrel—AR—Generic Transcription Pathway—ESR2—osteoporosis	1.51e-05	0.00128	CbGpPWpGaD
Levonorgestrel—Unspecified disorder of skin and subcutaneous tissue—Estradiol—osteoporosis	1.51e-05	0.000264	CcSEcCtD
Levonorgestrel—Urticaria—Zoledronate—osteoporosis	1.5e-05	0.000263	CcSEcCtD
Levonorgestrel—Discomfort—Estradiol—osteoporosis	1.5e-05	0.000263	CcSEcCtD
Levonorgestrel—ESR1—Signaling by ERBB4—IL6R—osteoporosis	1.5e-05	0.00127	CbGpPWpGaD
Levonorgestrel—Abdominal pain—Zoledronate—osteoporosis	1.5e-05	0.000262	CcSEcCtD
Levonorgestrel—Body temperature increased—Zoledronate—osteoporosis	1.5e-05	0.000262	CcSEcCtD
Levonorgestrel—Diarrhoea—Risedronate—osteoporosis	1.49e-05	0.000261	CcSEcCtD
Levonorgestrel—Gastrointestinal pain—Conjugated Estrogens—osteoporosis	1.49e-05	0.000261	CcSEcCtD
Levonorgestrel—Asthenia—Pamidronate—osteoporosis	1.49e-05	0.00026	CcSEcCtD
Levonorgestrel—Dizziness—Ethinyl Estradiol—osteoporosis	1.48e-05	0.000259	CcSEcCtD
Levonorgestrel—ESR1—Regulation of nuclear SMAD2/3 signaling—MYC—osteoporosis	1.47e-05	0.00124	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—PKM—osteoporosis	1.47e-05	0.00124	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—FDPS—osteoporosis	1.47e-05	0.00124	CbGpPWpGaD
Levonorgestrel—Pruritus—Pamidronate—osteoporosis	1.47e-05	0.000256	CcSEcCtD
Levonorgestrel—ESR1—Gene Expression—U2AF1—osteoporosis	1.47e-05	0.00124	CbGpPWpGaD
Levonorgestrel—Oedema—Estradiol—osteoporosis	1.46e-05	0.000255	CcSEcCtD
Levonorgestrel—AR—SIDS Susceptibility Pathways—IL1B—osteoporosis	1.45e-05	0.00123	CbGpPWpGaD
Levonorgestrel—Infection—Estradiol—osteoporosis	1.45e-05	0.000253	CcSEcCtD
Levonorgestrel—Urticaria—Conjugated Estrogens—osteoporosis	1.45e-05	0.000253	CcSEcCtD
Levonorgestrel—Dizziness—Risedronate—osteoporosis	1.44e-05	0.000252	CcSEcCtD
Levonorgestrel—Body temperature increased—Conjugated Estrogens—osteoporosis	1.44e-05	0.000252	CcSEcCtD
Levonorgestrel—Abdominal pain—Conjugated Estrogens—osteoporosis	1.44e-05	0.000252	CcSEcCtD
Levonorgestrel—CYP3A4—Biological oxidations—CYP27A1—osteoporosis	1.44e-05	0.00122	CbGpPWpGaD
Levonorgestrel—Shock—Estradiol—osteoporosis	1.43e-05	0.000251	CcSEcCtD
Levonorgestrel—Nervous system disorder—Estradiol—osteoporosis	1.43e-05	0.00025	CcSEcCtD
Levonorgestrel—ESR1—ATF-2 transcription factor network—IL6—osteoporosis	1.43e-05	0.0012	CbGpPWpGaD
Levonorgestrel—CYP3A4—Phase 1 - Functionalization of compounds—CYP19A1—osteoporosis	1.42e-05	0.0012	CbGpPWpGaD
Levonorgestrel—Vomiting—Ethinyl Estradiol—osteoporosis	1.42e-05	0.000249	CcSEcCtD
Levonorgestrel—CYP3A4—Metapathway biotransformation—CYP27A1—osteoporosis	1.42e-05	0.0012	CbGpPWpGaD
Levonorgestrel—Diarrhoea—Pamidronate—osteoporosis	1.42e-05	0.000248	CcSEcCtD
Levonorgestrel—Skin disorder—Estradiol—osteoporosis	1.42e-05	0.000248	CcSEcCtD
Levonorgestrel—AR—Gene Expression—RPL24—osteoporosis	1.41e-05	0.00119	CbGpPWpGaD
Levonorgestrel—Hyperhidrosis—Estradiol—osteoporosis	1.41e-05	0.000247	CcSEcCtD
Levonorgestrel—Rash—Ethinyl Estradiol—osteoporosis	1.41e-05	0.000246	CcSEcCtD
Levonorgestrel—Dermatitis—Ethinyl Estradiol—osteoporosis	1.41e-05	0.000246	CcSEcCtD
Levonorgestrel—Headache—Ethinyl Estradiol—osteoporosis	1.4e-05	0.000245	CcSEcCtD
Levonorgestrel—Hypersensitivity—Zoledronate—osteoporosis	1.39e-05	0.000244	CcSEcCtD
Levonorgestrel—CYP19A1—Metabolism—PGLS—osteoporosis	1.39e-05	0.00118	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—GPD2—osteoporosis	1.39e-05	0.00118	CbGpPWpGaD
Levonorgestrel—Vomiting—Risedronate—osteoporosis	1.39e-05	0.000242	CcSEcCtD
Levonorgestrel—Rash—Risedronate—osteoporosis	1.37e-05	0.00024	CcSEcCtD
Levonorgestrel—Dermatitis—Risedronate—osteoporosis	1.37e-05	0.00024	CcSEcCtD
Levonorgestrel—Dizziness—Pamidronate—osteoporosis	1.37e-05	0.00024	CcSEcCtD
Levonorgestrel—Headache—Risedronate—osteoporosis	1.37e-05	0.000239	CcSEcCtD
Levonorgestrel—Asthenia—Zoledronate—osteoporosis	1.36e-05	0.000237	CcSEcCtD
Levonorgestrel—PGR—Signaling Pathways—MGLL—osteoporosis	1.35e-05	0.00114	CbGpPWpGaD
Levonorgestrel—Hypersensitivity—Conjugated Estrogens—osteoporosis	1.34e-05	0.000235	CcSEcCtD
Levonorgestrel—Pruritus—Zoledronate—osteoporosis	1.34e-05	0.000234	CcSEcCtD
Levonorgestrel—Musculoskeletal discomfort—Estradiol—osteoporosis	1.33e-05	0.000232	CcSEcCtD
Levonorgestrel—Nausea—Ethinyl Estradiol—osteoporosis	1.33e-05	0.000232	CcSEcCtD
Levonorgestrel—Insomnia—Estradiol—osteoporosis	1.32e-05	0.000231	CcSEcCtD
Levonorgestrel—Vomiting—Pamidronate—osteoporosis	1.32e-05	0.00023	CcSEcCtD
Levonorgestrel—PGR—Signaling Pathways—LRP5—osteoporosis	1.31e-05	0.00111	CbGpPWpGaD
Levonorgestrel—Asthenia—Conjugated Estrogens—osteoporosis	1.31e-05	0.000229	CcSEcCtD
Levonorgestrel—Rash—Pamidronate—osteoporosis	1.31e-05	0.000228	CcSEcCtD
Levonorgestrel—Dermatitis—Pamidronate—osteoporosis	1.31e-05	0.000228	CcSEcCtD
Levonorgestrel—Dyspnoea—Estradiol—osteoporosis	1.3e-05	0.000227	CcSEcCtD
Levonorgestrel—Headache—Pamidronate—osteoporosis	1.3e-05	0.000227	CcSEcCtD
Levonorgestrel—Somnolence—Estradiol—osteoporosis	1.3e-05	0.000227	CcSEcCtD
Levonorgestrel—Diarrhoea—Zoledronate—osteoporosis	1.29e-05	0.000226	CcSEcCtD
Levonorgestrel—Nausea—Risedronate—osteoporosis	1.29e-05	0.000226	CcSEcCtD
Levonorgestrel—Pruritus—Conjugated Estrogens—osteoporosis	1.29e-05	0.000225	CcSEcCtD
Levonorgestrel—Dyspepsia—Estradiol—osteoporosis	1.28e-05	0.000225	CcSEcCtD
Levonorgestrel—CYP19A1—Metabolism—PNP—osteoporosis	1.27e-05	0.00108	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—ATIC—osteoporosis	1.27e-05	0.00108	CbGpPWpGaD
Levonorgestrel—Decreased appetite—Estradiol—osteoporosis	1.27e-05	0.000222	CcSEcCtD
Levonorgestrel—Gastrointestinal disorder—Estradiol—osteoporosis	1.26e-05	0.00022	CcSEcCtD
Levonorgestrel—Fatigue—Estradiol—osteoporosis	1.26e-05	0.00022	CcSEcCtD
Levonorgestrel—PGR—Signaling Pathways—LRP6—osteoporosis	1.26e-05	0.00106	CbGpPWpGaD
Levonorgestrel—Dizziness—Zoledronate—osteoporosis	1.25e-05	0.000219	CcSEcCtD
Levonorgestrel—Constipation—Estradiol—osteoporosis	1.25e-05	0.000218	CcSEcCtD
Levonorgestrel—Pain—Estradiol—osteoporosis	1.25e-05	0.000218	CcSEcCtD
Levonorgestrel—Diarrhoea—Conjugated Estrogens—osteoporosis	1.25e-05	0.000218	CcSEcCtD
Levonorgestrel—ESR1—AP-1 transcription factor network—IL6—osteoporosis	1.24e-05	0.00105	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Pancreatic Cancer Pathway—IGF1—osteoporosis	1.23e-05	0.00104	CbGpPWpGaD
Levonorgestrel—Nausea—Pamidronate—osteoporosis	1.23e-05	0.000215	CcSEcCtD
Levonorgestrel—SRD5A1—Metabolism—POMC—osteoporosis	1.23e-05	0.00104	CbGpPWpGaD
Levonorgestrel—PGR—Generic Transcription Pathway—ESR1—osteoporosis	1.21e-05	0.00102	CbGpPWpGaD
Levonorgestrel—Dizziness—Conjugated Estrogens—osteoporosis	1.21e-05	0.000211	CcSEcCtD
Levonorgestrel—Vomiting—Zoledronate—osteoporosis	1.2e-05	0.00021	CcSEcCtD
Levonorgestrel—AR—Generic Transcription Pathway—VDR—osteoporosis	1.2e-05	0.00102	CbGpPWpGaD
Levonorgestrel—Rash—Zoledronate—osteoporosis	1.19e-05	0.000209	CcSEcCtD
Levonorgestrel—Gastrointestinal pain—Estradiol—osteoporosis	1.19e-05	0.000209	CcSEcCtD
Levonorgestrel—Dermatitis—Zoledronate—osteoporosis	1.19e-05	0.000208	CcSEcCtD
Levonorgestrel—Headache—Zoledronate—osteoporosis	1.19e-05	0.000207	CcSEcCtD
Levonorgestrel—ESR1—Generic Transcription Pathway—ESR2—osteoporosis	1.17e-05	0.000985	CbGpPWpGaD
Levonorgestrel—AR—Integrated Breast Cancer Pathway—MYC—osteoporosis	1.16e-05	0.00098	CbGpPWpGaD
Levonorgestrel—Vomiting—Conjugated Estrogens—osteoporosis	1.16e-05	0.000203	CcSEcCtD
Levonorgestrel—Urticaria—Estradiol—osteoporosis	1.16e-05	0.000203	CcSEcCtD
Levonorgestrel—Body temperature increased—Estradiol—osteoporosis	1.15e-05	0.000202	CcSEcCtD
Levonorgestrel—Abdominal pain—Estradiol—osteoporosis	1.15e-05	0.000202	CcSEcCtD
Levonorgestrel—Rash—Conjugated Estrogens—osteoporosis	1.15e-05	0.000201	CcSEcCtD
Levonorgestrel—Dermatitis—Conjugated Estrogens—osteoporosis	1.15e-05	0.000201	CcSEcCtD
Levonorgestrel—Headache—Conjugated Estrogens—osteoporosis	1.14e-05	0.0002	CcSEcCtD
Levonorgestrel—PGR—Signaling by ERBB4—IL6—osteoporosis	1.14e-05	0.000962	CbGpPWpGaD
Levonorgestrel—Nausea—Zoledronate—osteoporosis	1.12e-05	0.000197	CcSEcCtD
Levonorgestrel—ESR1—Signaling Pathways—SOST—osteoporosis	1.1e-05	0.000928	CbGpPWpGaD
Levonorgestrel—ESR1—Gene Expression—RPL24—osteoporosis	1.09e-05	0.00092	CbGpPWpGaD
Levonorgestrel—Nausea—Conjugated Estrogens—osteoporosis	1.08e-05	0.000189	CcSEcCtD
Levonorgestrel—CYP19A1—Metabolism—CA2—osteoporosis	1.08e-05	0.000914	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—OXCT1—osteoporosis	1.08e-05	0.000914	CbGpPWpGaD
Levonorgestrel—Hypersensitivity—Estradiol—osteoporosis	1.07e-05	0.000188	CcSEcCtD
Levonorgestrel—PGR—Gene Expression—PSMA2—osteoporosis	1.07e-05	0.000905	CbGpPWpGaD
Levonorgestrel—PGR—Gene Expression—PSMA5—osteoporosis	1.07e-05	0.000905	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—TLN1—osteoporosis	1.06e-05	0.000896	CbGpPWpGaD
Levonorgestrel—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—osteoporosis	1.05e-05	0.000891	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—MGLL—osteoporosis	1.05e-05	0.000891	CbGpPWpGaD
Levonorgestrel—AR—SIDS Susceptibility Pathways—TNF—osteoporosis	1.05e-05	0.00089	CbGpPWpGaD
Levonorgestrel—Asthenia—Estradiol—osteoporosis	1.05e-05	0.000183	CcSEcCtD
Levonorgestrel—Pruritus—Estradiol—osteoporosis	1.03e-05	0.00018	CcSEcCtD
Levonorgestrel—CYP19A1—Integrated Breast Cancer Pathway—MYC—osteoporosis	9.98e-06	0.000843	CbGpPWpGaD
Levonorgestrel—Diarrhoea—Estradiol—osteoporosis	9.98e-06	0.000175	CcSEcCtD
Levonorgestrel—ESR1—Signaling Pathways—PTH1R—osteoporosis	9.94e-06	0.000839	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—CALCR—osteoporosis	9.94e-06	0.000839	CbGpPWpGaD
Levonorgestrel—Dizziness—Estradiol—osteoporosis	9.64e-06	0.000169	CcSEcCtD
Levonorgestrel—AR—Integrated Pancreatic Cancer Pathway—MYC—osteoporosis	9.62e-06	0.000812	CbGpPWpGaD
Levonorgestrel—AR—Integrated Pancreatic Cancer Pathway—TGFB1—osteoporosis	9.59e-06	0.00081	CbGpPWpGaD
Levonorgestrel—PGR—Gene Expression—ESR2—osteoporosis	9.57e-06	0.000808	CbGpPWpGaD
Levonorgestrel—Vomiting—Estradiol—osteoporosis	9.27e-06	0.000162	CcSEcCtD
Levonorgestrel—ESR1—Generic Transcription Pathway—VDR—osteoporosis	9.26e-06	0.000782	CbGpPWpGaD
Levonorgestrel—Rash—Estradiol—osteoporosis	9.2e-06	0.000161	CcSEcCtD
Levonorgestrel—Dermatitis—Estradiol—osteoporosis	9.19e-06	0.000161	CcSEcCtD
Levonorgestrel—AR—Generic Transcription Pathway—ESR1—osteoporosis	9.18e-06	0.000776	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—P4HB—osteoporosis	9.14e-06	0.000772	CbGpPWpGaD
Levonorgestrel—Headache—Estradiol—osteoporosis	9.14e-06	0.00016	CcSEcCtD
Levonorgestrel—CYP19A1—Metabolism—IDH2—osteoporosis	8.97e-06	0.000757	CbGpPWpGaD
Levonorgestrel—AR—Integrated Pancreatic Cancer Pathway—TNF—osteoporosis	8.96e-06	0.000757	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Breast Cancer Pathway—MYC—osteoporosis	8.94e-06	0.000755	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—PTH—osteoporosis	8.89e-06	0.000751	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—RAP1A—osteoporosis	8.74e-06	0.000738	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—CNR2—osteoporosis	8.67e-06	0.000732	CbGpPWpGaD
Levonorgestrel—Nausea—Estradiol—osteoporosis	8.66e-06	0.000152	CcSEcCtD
Levonorgestrel—CYP3A4—Phase 1 - Functionalization of compounds—POMC—osteoporosis	8.55e-06	0.000722	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—NFATC1—osteoporosis	8.53e-06	0.00072	CbGpPWpGaD
Levonorgestrel—AR—SIDS Susceptibility Pathways—IL6—osteoporosis	8.5e-06	0.000718	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—DKK1—osteoporosis	8.46e-06	0.000715	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—CYP27A1—osteoporosis	8.43e-06	0.000712	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—ACP5—osteoporosis	8.2e-06	0.000693	CbGpPWpGaD
Levonorgestrel—AR—Gene Expression—PSMA2—osteoporosis	8.16e-06	0.000689	CbGpPWpGaD
Levonorgestrel—AR—Gene Expression—PSMA5—osteoporosis	8.16e-06	0.000689	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—WNT1—osteoporosis	8.15e-06	0.000688	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism of lipids and lipoproteins—GPX1—osteoporosis	8.1e-06	0.000684	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—FGA—osteoporosis	7.93e-06	0.00067	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—MGLL—osteoporosis	7.89e-06	0.000667	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—LRP5—osteoporosis	7.71e-06	0.000651	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—TPI1—osteoporosis	7.62e-06	0.000644	CbGpPWpGaD
Levonorgestrel—PGR—Gene Expression—VDR—osteoporosis	7.59e-06	0.000641	CbGpPWpGaD
Levonorgestrel—CYP3A4—Biological oxidations—CYP19A1—osteoporosis	7.56e-06	0.000638	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metapathway biotransformation—CYP19A1—osteoporosis	7.45e-06	0.00063	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Pancreatic Cancer Pathway—MYC—osteoporosis	7.41e-06	0.000626	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Pancreatic Cancer Pathway—TGFB1—osteoporosis	7.39e-06	0.000624	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—LRP6—osteoporosis	7.37e-06	0.000623	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—PTHLH—osteoporosis	7.37e-06	0.000623	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—BMP2—osteoporosis	7.37e-06	0.000623	CbGpPWpGaD
Levonorgestrel—AR—Gene Expression—ESR2—osteoporosis	7.29e-06	0.000616	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—FGB—osteoporosis	7.21e-06	0.000609	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—P4HB—osteoporosis	7.17e-06	0.000606	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—GAPDH—osteoporosis	7.04e-06	0.000594	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—PSMA5—osteoporosis	6.96e-06	0.000588	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—PSMA2—osteoporosis	6.96e-06	0.000588	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Pancreatic Cancer Pathway—TNF—osteoporosis	6.9e-06	0.000583	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—RAP1A—osteoporosis	6.85e-06	0.000579	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling by ERBB4—IL6—osteoporosis	6.68e-06	0.000565	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—CALCA—osteoporosis	6.49e-06	0.000548	CbGpPWpGaD
Levonorgestrel—ESR1—Gene Expression—PSMA5—osteoporosis	6.29e-06	0.000531	CbGpPWpGaD
Levonorgestrel—ESR1—Gene Expression—PSMA2—osteoporosis	6.29e-06	0.000531	CbGpPWpGaD
Levonorgestrel—PGR—Generic Transcription Pathway—MYC—osteoporosis	6.27e-06	0.00053	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—TLN1—osteoporosis	6.22e-06	0.000526	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism of lipids and lipoproteins—POMC—osteoporosis	5.98e-06	0.000505	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—KL—osteoporosis	5.89e-06	0.000498	CbGpPWpGaD
Levonorgestrel—PGR—Gene Expression—ESR1—osteoporosis	5.8e-06	0.00049	CbGpPWpGaD
Levonorgestrel—AR—Gene Expression—VDR—osteoporosis	5.79e-06	0.000489	CbGpPWpGaD
Levonorgestrel—ESR1—Gene Expression—ESR2—osteoporosis	5.62e-06	0.000474	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—ENO1—osteoporosis	5.54e-06	0.000468	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—PSMA2—osteoporosis	5.46e-06	0.000461	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—PSMA5—osteoporosis	5.46e-06	0.000461	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—P4HB—osteoporosis	5.37e-06	0.000453	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—PTH—osteoporosis	5.22e-06	0.000441	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—RAP1A—osteoporosis	5.13e-06	0.000433	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—CNR2—osteoporosis	5.09e-06	0.00043	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—NFATC1—osteoporosis	5e-06	0.000423	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—DKK1—osteoporosis	4.97e-06	0.000419	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—WNT1—osteoporosis	4.78e-06	0.000404	CbGpPWpGaD
Levonorgestrel—AR—Generic Transcription Pathway—MYC—osteoporosis	4.78e-06	0.000403	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—FGA—osteoporosis	4.65e-06	0.000393	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—ADCY5—osteoporosis	4.62e-06	0.00039	CbGpPWpGaD
Levonorgestrel—CYP3A4—Biological oxidations—POMC—osteoporosis	4.54e-06	0.000384	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—SPP1—osteoporosis	4.47e-06	0.000377	CbGpPWpGaD
Levonorgestrel—ESR1—Gene Expression—VDR—osteoporosis	4.46e-06	0.000376	CbGpPWpGaD
Levonorgestrel—AR—Gene Expression—ESR1—osteoporosis	4.42e-06	0.000373	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—PTHLH—osteoporosis	4.33e-06	0.000365	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—BMP2—osteoporosis	4.33e-06	0.000365	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—PKM—osteoporosis	4.28e-06	0.000362	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—FDPS—osteoporosis	4.28e-06	0.000362	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—FGB—osteoporosis	4.23e-06	0.000358	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—PSMA2—osteoporosis	4.09e-06	0.000345	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—PSMA5—osteoporosis	4.09e-06	0.000345	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—PGLS—osteoporosis	4.06e-06	0.000343	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—GPD2—osteoporosis	4.06e-06	0.000343	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—IRS2—osteoporosis	4.04e-06	0.000341	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—LEP—osteoporosis	3.95e-06	0.000334	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—CALCA—osteoporosis	3.81e-06	0.000322	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—ESR1—osteoporosis	3.77e-06	0.000319	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—ATIC—osteoporosis	3.71e-06	0.000314	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—PNP—osteoporosis	3.71e-06	0.000314	CbGpPWpGaD
Levonorgestrel—ESR1—Generic Transcription Pathway—MYC—osteoporosis	3.68e-06	0.000311	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—ADCY5—osteoporosis	3.62e-06	0.000306	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—GPX1—osteoporosis	3.61e-06	0.000305	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—IRS1—osteoporosis	3.53e-06	0.000298	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—KL—osteoporosis	3.46e-06	0.000292	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—POMC—osteoporosis	3.39e-06	0.000287	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—MTHFR—osteoporosis	3.33e-06	0.000281	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—IL6R—osteoporosis	3.31e-06	0.00028	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—IGF1—osteoporosis	3.27e-06	0.000276	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—CA2—osteoporosis	3.16e-06	0.000267	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—OXCT1—osteoporosis	3.16e-06	0.000267	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—MGLL—osteoporosis	3.08e-06	0.00026	CbGpPWpGaD
Levonorgestrel—PGR—Gene Expression—MYC—osteoporosis	3.02e-06	0.000255	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—ADCY5—osteoporosis	2.71e-06	0.000229	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—POMC—osteoporosis	2.66e-06	0.000225	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—SPP1—osteoporosis	2.62e-06	0.000221	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—IDH2—osteoporosis	2.62e-06	0.000221	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—CYP27A1—osteoporosis	2.46e-06	0.000208	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—ACP5—osteoporosis	2.39e-06	0.000202	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—IRS2—osteoporosis	2.37e-06	0.0002	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—LEP—osteoporosis	2.32e-06	0.000196	CbGpPWpGaD
Levonorgestrel—AR—Gene Expression—MYC—osteoporosis	2.3e-06	0.000194	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—TPI1—osteoporosis	2.23e-06	0.000188	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—P4HB—osteoporosis	2.09e-06	0.000177	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—IRS1—osteoporosis	2.07e-06	0.000175	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—GAPDH—osteoporosis	2.05e-06	0.000173	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—RAP1A—osteoporosis	2e-06	0.000169	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—POMC—osteoporosis	1.99e-06	0.000168	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—MYC—osteoporosis	1.96e-06	0.000166	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—TGFB1—osteoporosis	1.96e-06	0.000165	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—IL6R—osteoporosis	1.94e-06	0.000164	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—IGF1—osteoporosis	1.92e-06	0.000162	CbGpPWpGaD
Levonorgestrel—ESR1—Gene Expression—MYC—osteoporosis	1.77e-06	0.00015	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—ENO1—osteoporosis	1.62e-06	0.000137	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—PSMA2—osteoporosis	1.59e-06	0.000135	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—PSMA5—osteoporosis	1.59e-06	0.000135	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—IL6—osteoporosis	1.48e-06	0.000125	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—CYP19A1—osteoporosis	1.29e-06	0.000109	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—MYC—osteoporosis	1.15e-06	9.73e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—TGFB1—osteoporosis	1.15e-06	9.71e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—ADCY5—osteoporosis	1.06e-06	8.92e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—GPX1—osteoporosis	1.05e-06	8.89e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—MTHFR—osteoporosis	9.71e-07	8.2e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—IL6—osteoporosis	8.66e-07	7.31e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—POMC—osteoporosis	7.77e-07	6.56e-05	CbGpPWpGaD
